Congress will continue to take a close look to ensure these taxpayer-funded programs are properly targeted and allocate resources to areas and patients who need it most.
Continue congressional oversight of health reauthorization programs to ensure taxpayer funds are properly targeted, spent as intended, and protective of patient privacy.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
The committee says Chairman Morgan Griffith led a markup of public health reauthorization bills, FDA oversight bills, and Medicare policies; all 10 listed measures were reported to the full committee by voice vote.
legacy_unverified · Source version not recorded · locator unknown
The full Energy and Commerce Committee reported 16 bills to the House, including H.R. 4348, H.R. 4541, H.R. 3747, H.R. 8209, H.R. 5160, H.R. 8205, H.R. 2715, H.R. 2821, H.R. 5347, and H.R. 1703, all by favorable roll-call votes.
legacy_unverified · Source version not recorded · locator unknown
Griffith's prepared statement says the markup included public health programs expiring at the end of the fiscal year and gave the subcommittee an opportunity to examine how to strengthen them.
legacy_unverified · Source version not recorded · locator unknown
The House repository memo lists the May 13 Health Subcommittee markup agenda and summarizes reauthorizations for vector-borne disease programs, breast cancer education, Project ECHO, school-based health centers, stem cell and cord blood programs, and ALS access programs.
legacy_unverified · Source version not recorded · locator unknown
The committee says Griffith led a hearing titled Examining the Medicare Physician Fee Schedule, MACRA, and Opportunities for Payment Reforms, focused on provider payment challenges, affordability, competition, and access.
legacy_unverified · Source version not recorded · locator unknown
Griffith's statement identifies MIPS reporting burdens, payment instability, consolidation risks, and costs to patients and the federal government as issues for the hearing to examine.
legacy_unverified · Source version not recorded · locator unknown
The committee states that Griffith joined letters to 10 states seeking information and documents on Medicaid program integrity, fraud, waste, and abuse.
legacy_unverified · Source version not recorded · locator unknown
Griffith said authorization bills require evaluating program impacts, whether funds are spent as intended, and whether patient privacy is protected; the page lists seven public health reauthorization bills reported to full committee by voice vote.
legacy_unverified · Source version not recorded · locator unknown
Griffith said he reintroduced the Risky Research Review Act in the 119th Congress, described his Energy and Commerce oversight of NIH and organ procurement practices, and said HHS began steps to decertify Network for Hope after his investigation into organ transplant safety failures.
legacy_unverified · Source version not recorded · locator unknown
HHS began decertification of Network for Hope after HRSA and CMS reviews found persistent patient safety failures, including 103 concerning cases and 73 patients with neurological signs incompatible with organ donation; CMS said providers that cannot safeguard patients and be responsible stewards of taxpayer dollars would be replaced.
Assessments
The promise was to continue congressional oversight, not necessarily to enact a final statutory change. The evidence shows Griffith, as Health Subcommittee chair/member of Energy and Commerce, held and led oversight-related hearings and markups on Medicare/MACRA, public health reauthorizations, FDA and Medicare policy, Medicaid program integrity, taxpayer spending, and patient privacy. The record also links his organ procurement oversight to same-term HHS decertification action. These activities directly match the promised federal oversight function during his current term.
The promise was an oversight commitment rather than a pledge to enact a specific statute. Same-term evidence shows Griffith, as House Energy and Commerce Health Subcommittee chair, led hearings and markups on health reauthorization programs, Medicare/MACRA payment oversight, FDA and Medicare policy bills, and Medicaid program-integrity inquiries. His statements directly addressed whether funds were spent as intended and whether patient privacy was protected. Because he materially conducted the promised congressional oversight during his current federal term, the outcome counts as delivered.